What is the intrinsic value of Alnylam?
As of 2025-12-22, the Intrinsic Value of Alnylam Pharmaceuticals Inc (ALNY) is
4.55 USD. This Alnylam valuation is based on the model Peter Lynch Fair Value.
With the current market price of 400.23 USD, the upside of Alnylam Pharmaceuticals Inc is
-98.86%.
Is Alnylam undervalued or overvalued?
Based on its market price of 400.23 USD and our intrinsic valuation, Alnylam Pharmaceuticals Inc (ALNY) is overvalued by 98.86%.
Alnylam Intrinsic Value - Valuation Summary
|
Range |
Selected |
Upside |
| a |
| DCF (Growth 5y) |
(376.95) - (117.18) |
(177.28) |
-144.3% |
| DCF (Growth 10y) |
(190.91) - (592.96) |
(284.34) |
-171.0% |
| DCF (EBITDA 5y) |
(26.67) - (29.77) |
(1,234.50) |
-123450.0% |
| DCF (EBITDA 10y) |
(53.16) - (56.83) |
(1,234.50) |
-123450.0% |
| Fair Value |
4.55 - 4.55 |
4.55 |
-98.86% |
| P/E |
4.39 - 15.43 |
7.73 |
-98.1% |
| EV/EBITDA |
30.81 - 87.65 |
35.28 |
-91.2% |
| EPV |
(34.78) - (45.59) |
(40.18) |
-110.0% |
| DDM - Stable |
4.13 - 17.89 |
11.01 |
-97.2% |
| DDM - Multi |
(111.22) - (372.00) |
(171.00) |
-142.7% |
Alnylam Intrinsic Value - Key Valuation Metrics
| Market Cap (mil) |
52,874.39 |
| Beta |
1.01 |
| Outstanding shares (mil) |
132.11 |
| Enterprise Value (mil) |
52,424.41 |
| Market risk premium |
4.60% |
| Cost of Equity |
7.62% |
| Cost of Debt |
7.41% |
| WACC |
7.62% |